Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nightstar Therapeutics (NITE) Share Price

Media headlines about Nightstar Therapeutics (NASDAQ:NITE) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.2625160242278 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Nightstar Therapeutics (NASDAQ:NITE) opened at $12.44 on Friday. The company has a market capitalization of $349.57 and a P/E ratio of -24.88. Nightstar Therapeutics has a 12-month low of $11.99 and a 12-month high of $24.93.

A number of research firms have recently commented on NITE. Wedbush assumed coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $19.00 price objective on the stock. Leerink Swann initiated coverage on Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price for the company. Chardan Capital initiated coverage on Nightstar Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $40.00 price objective for the company. Jefferies Group initiated coverage on Nightstar Therapeutics in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on Nightstar Therapeutics in a research note on Monday, October 23rd. They set an “outperform” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $30.20.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nightstar Therapeutics (NITE) Share Price” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/02/11/nightstar-therapeutics-nite-getting-somewhat-positive-news-coverage-analysis-shows.html.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Insider Buying and Selling by Quarter for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply